ライフサイエンスコーパス: immunization

1 enggara) for Indonesia's Expanded Program on Immunization.

2 ne complexes are a major determinant of this immunization.

3 than those with DNA or recombinant E protein immunization.

4 can be greater than that achieved by direct immunization.

5 une response in the context of infection and immunization.

6 nd comparable peak responses after the final immunization.

7 bs have reinvigorated the concept of passive immunization.

8 fficacy in countries with universal neonatal immunization.

9 xpansion of Tfr cells after T-cell-dependent immunization.

10 ncrease in breadth and potency following Env immunization.

11 major cause of chronic HBV infection despite immunization.

12 stemic production of bNAbs in the absence of immunization.

13 an additional, previously unknown benefit of immunization.

14 , resulting in equivalent immunity to direct immunization.

15 tioning, and T cell activation after protein immunization.

16 terologous Pf7G8 parasites 33 wk after final immunization.

17 ers and high-affinity antibody after protein immunization.

18 reting cells and memory cells generated upon immunization.

19 vaccine formulations to overcome suboptimal immunization.

20 ble mice were unable to respond to NP-Ficoll immunization.

21 long-term humoral immune response following immunization.

22 ster after an inactivated JE vaccine primary immunization.

23 nization and were not enhanced by subsequent immunizations.

24 eastfeeding, pacifier use, room sharing, and immunizations.

25 inform GBS interventions including maternal immunization?

26 ovider knowledge of adverse events following immunization (11% increase), availability of RI micropla

27 linics, and mobilizing their communities for immunization activities (including poliovirus and other

28 Although monthly supplementary immunization activities (SIAs) continued, the targeting

29 nization (RI) services through supplementary immunization activities (SIAs) is an important benefit o

30 and defaulter tracing, monitoring of routine immunization activities, and support of district immuniz

31 rks, and the need for periodic supplementary immunization activities.

32 e show that both the vector and the route of immunization affected the level of CD4(+) T-cell respons

33 Herein, we demonstrate that passive immunization against the Vbeta8-targeting SAg streptococ

34 e newly characterized oligomers as an active immunization agent targeting amyloid self- assembly in a

35 more effective than the humoral or cellular immunization alone.

36 se inhibitor applied beginning on the day of immunization ameliorated initial course of disease, simi

37 obulin and active systemic anaphylaxis after immunization and challenge.

38 We interviewed immunization and cold-chain staff, assessed equipment, a

39 represents a promising strategy for maternal immunization and for other RSV vaccine target population

40 o areas of expertise were applied to broader immunization and mother, newborn and child health goals

41 er expanded its messaging to promote routine immunization and other health and sanitation interventio

42 lts highlight the role of Cas9 during CRISPR immunization and provide a useful tool to study this rar

43 his system can mainly be used for sublingual immunization and the development of "printed vaccine tec

44 sustain serum Ab responses following antigen immunization and viral infections.

45 esponses in the blood peaked after the first immunization and were not enhanced by subsequent immuniz

46 h body weight, mode of delivery and feeding, immunizations, and medical events) were recorded.

47 pment, the challenges of eliciting bnAbs via immunizations, and the putative central roles of Tfh cel

48 Wide-scale prevention through immunization appears to be within reach for respiratory

49 vaccine research is developing a successful immunization approach for inducing broadly neutralizing

50 that skin vaccination using MN is a superior immunization approach with the potential to overcome imm

51 NAbs and has led to the "germline-targeting" immunization approach.

52 born to mothers who received a prepregnancy immunization, are blunted.

53 The objective includes strengthening routine immunization as the primary pillar to sustaining high po

54 cy dialogue about polio vaccines and routine immunization at multiple levels.

55 Relative to baseline, iDCpp65 immunization boosted the output of effector memory CD4(+

56 ponse following influenza virus infection or immunization.Broadly reactive antibodies that recognize

57 , shelter, and health care access (including immunization), but a beneficial effect in countering wat

58 We assessed immunization by direct venous inoculation of aseptic, pu

59 vided to the South Sudan Expanded Program on Immunization by STOP volunteers, implementing partners,

60 In May 2014, an immunization campaign was launched in SLSJ, using the 4-

61 responses elicited by vaccination or passive immunization can inhibit sporozoite and ookinete infecti

62 e, and evidence-based advice on vaccines and immunization challenges.

63 heir frequency in the repertoires of the two immunization classes.

64 This peptide also only required a single immunization (compared with three immunizations with the

65 ice were exposed to Pneumocystis murina Pca1 immunization completely protected nearly all mice, simil

66 , multiple surveys have indicated persistent immunization coverage gaps.

67 ockets witnessed an increase in full routine immunization coverage.

68 PolioPlus program, participating in national immunization days, assisting with surveillance, working

69 HO's) Strategic Advisory Group of Experts on Immunization deemed that all countries must simultaneous

70 Despite progress in vaccine development and immunization delivery systems worldwide, populations in

71 Immunization during pregnancy is the most effective mean

72 Immunization effectively prevented carriage with only 1

73 DNA immunization efficacy was optimized by i.m. delivery via

74 CD4 T cells following Ad5 immunization exhibited impaired Th1 lineage commitment,

75 ong Th1 and Th17 immune responses in vivo in immunization experiments in mice and conferred protectio

76 IgG from rabbit serum that was taken before immunization failed to develop any of these changes.

77 Only mucosal rFWPV immunizations followed by systemic rAd boost significant

78 dy fragments confers effective intracellular immunization for preventing chronic viral replication an

79 nefits, 3xTg and wild-type mice received tau immunization from 2-6 months of age.

80 Unexpectedly, Pca1 immunization generated cross-reactive antibody that reco

81 -funded personnel allocate their time toward immunization goals and activities beyond those associate

82 with GP-alone, GP-alpha-syn (active humoral immunization), GP+RAP, or GP+RAP/alpha-syn (combined act

83 erproliferation of their GC compartment upon immunization, had reduced MHCII surface expression on GC

84 Hepatitis B virus (HBV) immunization has been effectively preventing chronic HBV

85 ) or inverse agonist JTE907 (3 mg/kg) during immunization heightens the intensity and breadth of anti

86 nsition, the South Sudan Expanded Program on Immunization human resources development project was lau

87 diated selection, and were reduced following immunization, immune checkpoint blockade or aging.

88 y and secondary antibody responses post-RABV immunization.IMPORTANCE Extending humoral immune respons

89 that infants can robustly respond to HIV Env immunization.IMPORTANCE More than 150,000 pediatric HIV

90 a previous DENV3 infection were recalled by immunization.IMPORTANCE The dengue epidemic presents a g

91 ted funded female human papillomavirus (HPV) immunization in 2007, followed by a targeted male vaccin

92 esulted in much greater immunity than direct immunization in 5-wk-old pups (ex vivo assay of pup sple

93 poliovirus vaccine, strengthening of routine immunization in countries with extensive polio resources

94 this problem is important for strategies of immunization in disease spreading, and influence maximiz

95 cidence prior to and following childhood PCV immunization in South Africa.

96 Recommendations for using passive immunization in the general population or for therapy in

97 drugs and reported she was up-to-date on her immunizations, including those for pneumonia and flu.

98 ted into the late disease stage (day 56 post-immunization), indicating the presence of a continuous g

99 national program managers to monitor the key immunization indicators and stratify by high-risk and no

100 th immunizing antigen, we found that chronic immunization induced antigen-specific serological respon

101 ndergo Ag-driven activation and join ongoing immunization-induced GC responses.

102 Thus, stepwise immunization initiates CD4bs-bnAb responses, but immune

103 ion, suggesting that immunoevasion after RBD immunization is accompanied by loss of viral fitness.

104 hat the quality of pTfh cells at the time of immunization is important for influenza vaccine response

105 Whether they might benefit from maternal immunization is unknown.

106 m management systems or by reinforcing local immunization managers' abilities, among others.

107 rs of measles, mumps, rubella, and varicella immunization may offer improved disease control.

108 known whether combining humoral and cellular immunization might act synergistically to reduce inflamm

109 mplete Freund's adjuvant (CFA)-evoked active immunization models compared to the reference SSAO inhib

110 Local immunization modified favorably the course of infection,

111 th homologous Pf parasites 19 wk after final immunization, nine (64%) of 14 (95% CI, 35-87%) vaccinat

112 In summary, prophylactic tau immunization not only prevents tau pathology but also Ab

113 s caused by the vaccine Oka strain following immunization of a 78-year-old woman with live zoster vac

114 Immunization of C57BL/6 mice with CPS-CRM197 produced hi

115 Immunization of cows may provide an avenue to rapidly ge

116 ications, including bacterial strain typing, immunization of cultures, autoimmunity or self-targeted

117 Passive immunization of DENV-infected mice with polyclonal anti-

118 utralizing nanobodies by phage display after immunization of dromedaries with different soluble trime

119 Immunization of ferrets with beta-propiolactone-inactiva

120 Lastly, immunization of human-antibody transgenic animals with a

121 A single intramuscular immunization of immunocompetent mice with the MVA-ZIKV-N

122 We previously reported that immunization of infants with an MF59-adjuvanted recombin

123 Intradermal immunization of mice against hepatitis B surface antigen

124 Moreover, on immunization of mice and rabbits, MBC4 induced cross-rea

125 ycoprotein D (gD) and that the intramuscular immunization of mice results in strong antiviral humoral

126 Immunization of mice with an optimized heroin-tetanus to

127 optimized GC-coated LPN adjuvant upon nasal immunization of mice with the recombinant Ct fusion anti

128 Following immunization of mice, serologic analysis demonstrated th

129 ed them to virus-like particles, followed by immunization of mice.

130 Immunization of nonhuman primates with these novel NYVAC

131 A single immunization of rhesus macaques elicited a rapid and rob

132 Our results demonstrate that immunization of rhesus macaques with NP adjuvants mixed

133 We find that immunization of rhesus macaques with the pentavalent vac

134 Immunization of rodents with BBI39, or a diverse paralog

135 ies may be most efficacious following active immunization or passive administration.IMPORTANCE Cytome

136 However, even then, patients with broad immunization or rare haplotypes may not have suitable do

137 of therapeutics as compared to conventional immunization or synthetic library selection strategies.

138 depends crucially on the temporal pattern of immunization (or selection forces).

139 opharyngeal infection; however, only passive immunization, or vaccination with inactive SpeA, resulte

140 Spatiotemporal variation in immunization performance and population movement pattern

141 : loss in B cell diversity across successive immunization periods against different variants, and the

142 lth to ensure sustainable, evidence-informed immunization policies that are trusted and accepted by t

143 programs for polio eradication, assisting at immunization posts and clinics, and mobilizing their com

144 ed from 2015-2016, the Advisory Committee on Immunization Practices made an interim recommendation no

145 ine in accordance with Advisory Committee on Immunization Practices recommendations should be encoura

146 In the field of dendritic cell based genetic immunization, previously we showed that liposomes of cat

147 1 (Th1) immune responses, whereas high-dose immunization primes responses characterized by regulator

148 016.The strong commitment of governments and immunization professionals to polio eradication and an e

149 Gs in the introduction of IPV in the routine immunization program and the lessons learned.

150 virus (HPV) vaccine among girls in the Dutch immunization program has plateaued at around 60%.

151 om meetings and personal communications with immunization program managers.

152 MR countries introduced IPV in their routine immunization program, including all of the countries at

153 roduce rotavirus vaccine into their national immunization program.

154 priority health programs like the Universal Immunization Program.

155 nly several countries with a funded male HPV immunization program.

156 for almost all vaccines contained in global immunization programs and influence immune response for

157 hree particular lessons for other health and immunization programs can be drawn from the experience o

158 Before the switch, immunization programs globally had been using approximat

159 njugate vaccines (PCVs) are used in national immunization programs in many developing countries.

160 eir employment would potentially disrupt the immunization programs in their countries and create a se

161 tivated polio vaccine (IPV) into the routine immunization programs of all countries using oral polio

162 tOPV highlights the adaptability of national immunization programs to new procedures, and identifies

163 te vaccine 13 (PCV13), are used in childhood immunization programs worldwide, but direct comparisons

164 d personnel provide critical support for the immunization programs, and sudden discontinuation of the

165 dedicated to tasks related to strengthening immunization programs, other than polio eradication.

166 repares for the full removal of all OPV from immunization programs, this need for lead time and consi

167 ost-effectiveness of which vaccine to use in immunization programs.

168 at the country level reinforces the national immunization programs.

169 PV2 by ceasing use of tOPV in their national immunization programs.

170 ptions) may be a useful strategy to increase immunization rates and prevent outbreaks of vaccine-prev

171 trategic Advisory Group of Experts (SAGE) on Immunization recommended conducting this synchronized sw

172 822 were from vaccinated women according to immunization record, 1021 from women self-reporting vacc

173 n infants aged less than 2 months, antenatal immunization reduced annual pertussis incidence by 60%,

174 candidate; when we are able to optimize the immunization regimen (dose, interval between doses, and

175 n promote Abeta deposition, and that a short immunization regimen can have a long-lasting beneficial

176 maintained on an AP diet, despite comparable immunization regimens.

177 Immunization register data were abstracted from December

178 ne manufacturers, and the private sector for immunization-related initiatives.

179 istry of Public Health's Expanded Program on Immunization requested technical support to improve mapp

180 move parents' ability to opt-out from school immunization requirements on the basis of religious or p

181 Furthermore, SLT17 (pCZ1) or SLT18 (pCZ1) immunization resulted in 83% or 50% heterologous protect

182 Active immunization resulted in higher serological total IgG, I

183 Remarkably, BG505 SOSIP immunization resulted in rapid elicitation of broad and

184 GP-alpha-syn or GP+RAP/alpha-syn immunizations resulted in a 30-45% reduction in alpha-sy

185 WHO's Strategic Advisory Group of Experts on Immunization reviewed available data and concluded that

186 igh risk for polio transmission with routine immunization (RI) and other selected primary healthcare

187 dertaken, with specific focus on the routine immunization (RI) component.

188 tivated polio vaccine (IPV) into its routine immunization (RI) schedule in March 2015 and was the pil

189 The potential to strengthen routine immunization (RI) services through supplementary immuniz

190 lded greater efficacy than any other primary immunization route alone.

191 vaccine was used to assess the impact of the immunization route on vaccine efficacy.

192 The hierarchical rankings of primary immunization route with respect to efficacy were s.c. >/

193 IPV) after its introduction into the routine immunization schedule in Bangladesh.

194 Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2015.

195 ion of at least one dose of IPV into routine immunization schedules in 126 all OPV-using countries by

196 mumps-rubella-varicella (MMRV) vaccine, into immunization schedules should be evaluated from a benefi

197 ltiple-injection visits included in national immunization schedules.

198 cine and subsequent switch to their national immunization schedules.The purpose of this article is to

199 CDV attachment protein according to the same immunization scheme died.

200 Pn3P-specific CD4(+) T cells utilizing mouse immunization schemes that induce Pn3P-specific IgG respo

201 In comparison with repetitive Env immunizations, sequential Env administration rescue aner

202 unding to maintain and to strengthen routine immunization services and other maternal, neonatal, and

203 his legacy also includes support for routine immunization services and vaccine introductions and camp

204 vices (BPHS) program has increased access to immunization services for children living in rural Afgha

205 y and high vaccine wastage in small outreach immunization sessions might reduce its impact on populat

206 rmore, memory CD8(+) T cells generated by MA immunization significantly expanded upon locally adminis

207 e motivation, engagement, and cooperation of immunization staff and decision makers across all nation

208 sts may be more appropriate for modeling the immunization strategies aimed at preventing HIV disease

209 ysfunction should be considered in designing immunization strategies aimed at preventing HIV disease

210 This raises the prospect that intracellular immunization strategies that focus on cellular component

211 sequence modifications may be beneficial for immunization strategies that seek to minimize off-target

212 e mechanisms and will aid in optimization of immunization strategies to induce V2 apex bnAb responses

213 espite employing disparate viral vectors and immunization strategies, consistently identify a role fo

214 a consideration when designing vaccines and immunization strategies.

215 ples and scientific premises for the passive immunization strategy, including existing and emerging A

216 Immunization studies in mice showed that VLPs generated

217 ne-bound Env, 4-2.J41, may be beneficial for immunization studies using various prime-boost strategie

218 er after 2 years compared with 4 weeks after immunization, suggesting CD161 is a marker for long-live

219 nd in germinal center cells after deliberate immunization, suggesting that ABCs have undergone mild s

220 jection of A2aR agonist, CGS21680, following immunization suppressed T follicular differentiation, GC

221 opulation comparisons were from the National Immunization Survey-Teen and the National Health Intervi

222 ced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasing the maximum

223 nd implementation of the dashboard to assess immunization system performance allowed national program

224 ing various aspects of the performance of an immunization system.

225 To monitor immunization-system strengthening in the Polio Eradicati

226 work and stakeholder consultations, the IPV Immunization Systems Management Group (IMG) presented a

227 The article concludes by considering how the Immunization Systems Management Group of the Global Poli

228 succeeded because of the ability of even the immunization systems operating under hardship conditions

229 ts of the endgame plan include strengthening immunization systems using polio assets, introducing ina

230 eived to conduct tasks to strengthen routine immunization systems, and the type of tasks they have co

231 In certain countries with very weak immunization systems, GPEI-funded personnel provide crit

232 studies demonstrate that active and passive immunizations targeting alpha-syn partially ameliorate b

233 nization activities, and support of district immunization task teams, as well as promotion of health

234 National Immunization Technical Advisory Groups (NITAGs) are esta

235 Remarkably, upon immunization the gamma134.5 mutant induces protection ag

236 valid epitope for the development of future immunization therapy.

237 loped is immunotherapy-specifically, passive immunization through administration of exogenous monoclo

238 provide an opportunity to strengthen routine immunization, through strengthening program management s

239 tion of inactivated polio vaccine in routine immunization to mitigate against risk of vaccine-associa

240 ose fractional-IPV schedule could extend IPV immunization to more children.

241 that a skin-applied 4M2e-tFliC MNP boosting immunization to seasonal vaccine recipients may be a rap

242 ting entry of new B cell clones into ongoing immunization-triggered GC responses.

243 Passive immunization using Abeta-specific antibodies has been de

244 Pfs25 in complex with antibodies elicited by immunization via Pfs25 virus-like particles in human imm

245 serum IgG response in IgA(-/-) mice after CT immunization was microbiota dependent and was associated

246 The T-cell response to immunization was similar between genotypes, suggesting t

247 Planning started early, routine immunization was strengthened, and technical and financi

248 lethal influenza challenge seven months post-immunization when using CDN adjuvant doses up to 100-fol

249 G-MNAs was comparable to that of intradermal immunization whether it was evaluated by humoral or cell

250 Immunization with 3.2 x 10(3) (group I) or 1.28 x 10(4)

251 ntly (P < .01) reduced immediately following immunization with 30 microg or 100 microg of GEN-003.

252 Immunization with 30 mug of nucleoside-modified ZIKV mRN

253 of antisera generated in mice and rabbits by immunization with a hypoallergenic Cyp c 1 mutant inhibi

254 r mouse and rabbit IgG antibodies induced by immunization with a hypoallergenic mutant of the major c

255 Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneou

256 ory has previously demonstrated that passive immunization with an anti-tau antibody, HJ8.5, decreased

257 Furthermore, therapeutic immunization with an innovative prime/pull vaccine, base

258 Lastly, passive immunization with anti-OmpA MAbs did not confer protecti

259 taining vaccines on N. cinerea We found that immunization with Bexsero elicits serum bactericidal act

260 We showed that immunization with DCs, engineered to overexpress 25-hydr

261 Importantly, although sequential immunization with DNA and Ad5 maximized antitumor effica

262 Immunization with either disulfide or thioether linked v

263 Finally, immunization with either TraM or anti-TraM antiserum red

264 occal pyrogenic exotoxin A (SpeA), or active immunization with either wild-type or a nonfunctional Sp

265 lthough the functions of these genes and how immunization with fHbp-containing vaccines could affect

266 Thus, mucosal immunization with FWPV-based vaccines should be consider

267 e CPS component of the glycoconjugate, while immunization with Hcp1 and TssM produced high-titer IgG

268 germinal center formation after intradermal immunization with HIV p24-coated polylactic acid nanopar

269 Anti-HIV passive immunization with human neutralizing monoclonal antibodi

270 es and in both CD4 and CD8 T cells following immunization with LdCen(-/-) Upon challenge with wild-ty

271 o C-PfCSP from European donors who underwent immunization with live Pf sporozoites (PfSPZ Challenge)

272 Immunization with low doses of gp96 primes T helper type

273 in vivo after influenza virus infection and immunization with model antigens.

274 Sequential immunization with mutationally distant variants is shown

275 nt in GM-CSF are resistant to EAE induced by immunization with myelin oligodendrocyte glycoprotein (M

276 Subcutaneous immunization with neoglycoconjugate protected mice from

277 However, only antibodies induced by means of immunization with NtCFlg fused to the C-terminus of Bet

278 Immunization with optimal doses of RSV F antigens in the

279 estrogen receptors on the immune response by immunization with OVA and induction of chronic graft-ver

280 ning region 3 (CDR3beta) sequences following immunization with ovalbumin administered with complete F

281 nst the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine.

282 In both species, a single dose of intranasal immunization with PIV5-vectored vaccines was able to pro

283 Heterologous prime-boost immunization with plasmid DNA and viral vector vaccines

284 xpression in primary GC responses to vaccine immunization with protein antigen and adjuvant: B7 was r

285 ies blocking allergic patients' IgE, but not immunization with rBet v 1 via PDS alone.

286 A26-39 mucosal antibodies obtained following immunization with recombinant B. subtilis spores were ab

287 urthermore, CD8(+) immune T cells induced by immunization with recombinant GRA6Nt were eventually cap

288 ccine research to elicit these antibodies by immunization with recombinant mimics of the viral spike.

289 nd can trigger anti-Id immune responses, but immunization with several nonadjuvanted isologous IgG mA

290 r the expansion of Ag-specific B cells after immunization with SRBCs.

291 el mouse model of autoimmune cholangitis via immunization with syngeneic bile duct protein (BDP).

292 significantly less Ag-specific IgM Abs upon immunization with T cell-independent Ags, and they are m

293 ificantly reduced numbers of LLPCs following immunization with T-dependent antigens or infection with

294 Here we show that immunization with these lipid-polymer hybrid nanoparticl

295 novel mouse model of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendrit

296 letely protected nearly all mice, similar to immunization with whole Pneumocystis organisms.

297 Passive immunizations with antisera targeting outer membrane pro

298 In rabbit immunizations with native-like trimers of the 327c isola

299 d a single immunization (compared with three immunizations with the parent peptide) to induce complet

300 as further amplified with cholera toxin (CT) immunization without causing intestinal inflammation.